605197
Thrombin-Activatable Fibrinolysis Inhibitor, Human
Plasma Procarboxypeptidase B, TAFI
For general questions please contact our Customer Service:
Merck KGaA
Frankfurter Str. 250
64293 Darmstadt
Germany
Phone: +49 6151 72-0
Fax: +49 6151 72 2000
15 February 2012
loading
Native thrombin-activatable fibrinolysis inhibitor from human liver. Single chain glycoprotein synthesized in the liver. Circulates in plasma as a zymogen at a concentration of 50 nM. Activated by thrombin-thrombomodulin complex by proteolytic cleavage at Arg92. Believed to play an important role in interaction between the procoagulant, anticoagulant, and fibrinolytic systems.
| Product information | |||
|---|---|---|---|
| Form | Liquid | ||
| Formulation | In 150 mM NaCl, 20 mM HEPES, pH 7.4. | ||
| Molar mass | 60000 | ||
| Specific activity | ≥2-9 units/mg protein | ||
| Unit definition | One unit is defined as the amount of enzyme that will hydrolyze 1 µM Hip-L-Arg per min at 25°C, pH 7.65. | ||
| Purity | ≥95% by SDS-PAGE | ||
| Source | Prepared from serum that has been shown by certified tests to be negative for HBsAg and for antibodies to HIV and HCV. | ||
| Store and ship information | |||
|---|---|---|---|
| Storage | ≤ -70°C | ||
| Ship |
Dry Ice Only
Standard Handling |
||
